Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Opella is Sanofi’s consumer healthcare business unit focusing ... Its portfolio primarily encompasses products related to Pain and inflammation, Digestive wellness, Allergy, Cough, cold and ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash about the pharmaceutical company's deal with a US private equity firm.

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines.

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer ...

Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business ... We sell different types of products and services to both investment professionals and ...

Clayton Dubilier & Rice LLC finally won the auction for the Opella consumer health-care business being separated from France’s Sanofi SA ... Opella’s product range needs reconfiguring and ...

PARIS, Oct 17 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Thursday it was "surprised" by a renewed, higher offer for its consumer ... today of these products that are ...

Together, CD&R and Sanofi will support Opella’s growth strategy as a pure-play, global, and fast-moving consumer healthcare company ... including details by product and quarter, are expected to be ...

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash about the pharmaceutical company's deal with a US private equity firm.